Clinical trial · Interventional
Hypofractionated Radiation Therapy for Glioblastoma
Hypofractionated Radiation Therapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
NCT03212235CI-TRIAL-00028551unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Notwithstanding major improvements in treatment modalities, the prognosis of patients with glioblastoma is poor. Hypofractionated radiation therapy as an alternative of the standard 6-week regimen could be an attractive approach as an effort to prevent tumor cell repopulation and reduction the total treatment period promoting patient comfort and convenience.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma Multiforme | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hypofractionated radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Hypofractionated radiation therapy
- description
- Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week. After a 30-days break, adjuvant temozolomide days 1-5 every 28 days for 6 cycles.
- interventionNames
- Radiation: Hypofractionated radiation therapy
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 24 months
- description
- From date of the start of treatment to date of death due to any cause.
Secondary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients 18 to 70 years of age with newly diagnosed and histologically confirmed glioblastoma. * WHO performance status of 2 or less and adequate hematologic, renal, and hepatic function. Exclusion Criteria: * Prior diagnosis of cancer, unless disease free for \> 3 years * Previous history of radiotherapy in the head and neck region (except initial larynx tumor - T1, T2 / N0M0). * Specific severe, active co-morbidities * Tumor located in the brainstem * Presence of leptomeningeal carcinomatosis * Multicentric tumor
References
Publications (0)
Data not yet available
No reference posted for this study.